Interferon-α treatment of Behcet's disease

J. Desmond O'Duffy, Kenneth Calamia, Stanley Cohen, Jorg J. Goronzy, David Herman, Joseph Jorizzo, Cornelia Weyand, Eric Lawrence Matteson

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Objective. To determine if interferon-α (IFN-α) is effective in Behcet's disease (BD). Methods. Ten patients having active BD were entered into a 6 month open label trial of IFN-α therapy given by self-administered dose of 3 million units subcutaneously daily. Provision was made for downward or upward dosing depending on predetermined responses. Four study centers followed the same protocol. Patients having ocular or neurologic inflammation at onset of the study were excluded. Results. Seven patients completed the trial, while 3 were removed at 3 and 4 months for side effects or lack of efficacy. There was a substantial reduction in the number of oral and genital ulcers, cutaneous lesions, and articular signs and symptoms by the end of the study. Pain scores, global assessments, and prednisone dose also declined. The IFN-α dose at end of study averaged 1.5 million units. Significant side effects, besides the anticipated flu-like syndrome experienced by all the patients, included single instances of seizure, psychosis, psoriasis, and hyperthyroidism. Conclusion. The results suggest that IFN-α is effective therapy for some manifestations of Behcet's disease.

Original languageEnglish (US)
Pages (from-to)1938-1944
Number of pages7
JournalJournal of Rheumatology
Volume25
Issue number10
StatePublished - Oct 1998

Fingerprint

Behcet Syndrome
Interferons
Oral Ulcer
Hyperthyroidism
Therapeutics
Prednisone
Psoriasis
Psychotic Disorders
Nervous System
Signs and Symptoms
Epilepsy
Joints
Inflammation
Pain
Skin

Keywords

  • Behcet's disease
  • Interferon-α

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

O'Duffy, J. D., Calamia, K., Cohen, S., Goronzy, J. J., Herman, D., Jorizzo, J., ... Matteson, E. L. (1998). Interferon-α treatment of Behcet's disease. Journal of Rheumatology, 25(10), 1938-1944.

Interferon-α treatment of Behcet's disease. / O'Duffy, J. Desmond; Calamia, Kenneth; Cohen, Stanley; Goronzy, Jorg J.; Herman, David; Jorizzo, Joseph; Weyand, Cornelia; Matteson, Eric Lawrence.

In: Journal of Rheumatology, Vol. 25, No. 10, 10.1998, p. 1938-1944.

Research output: Contribution to journalArticle

O'Duffy, JD, Calamia, K, Cohen, S, Goronzy, JJ, Herman, D, Jorizzo, J, Weyand, C & Matteson, EL 1998, 'Interferon-α treatment of Behcet's disease', Journal of Rheumatology, vol. 25, no. 10, pp. 1938-1944.
O'Duffy JD, Calamia K, Cohen S, Goronzy JJ, Herman D, Jorizzo J et al. Interferon-α treatment of Behcet's disease. Journal of Rheumatology. 1998 Oct;25(10):1938-1944.
O'Duffy, J. Desmond ; Calamia, Kenneth ; Cohen, Stanley ; Goronzy, Jorg J. ; Herman, David ; Jorizzo, Joseph ; Weyand, Cornelia ; Matteson, Eric Lawrence. / Interferon-α treatment of Behcet's disease. In: Journal of Rheumatology. 1998 ; Vol. 25, No. 10. pp. 1938-1944.
@article{a36a10fd01ca4e4f8d9328cef20e8953,
title = "Interferon-α treatment of Behcet's disease",
abstract = "Objective. To determine if interferon-α (IFN-α) is effective in Behcet's disease (BD). Methods. Ten patients having active BD were entered into a 6 month open label trial of IFN-α therapy given by self-administered dose of 3 million units subcutaneously daily. Provision was made for downward or upward dosing depending on predetermined responses. Four study centers followed the same protocol. Patients having ocular or neurologic inflammation at onset of the study were excluded. Results. Seven patients completed the trial, while 3 were removed at 3 and 4 months for side effects or lack of efficacy. There was a substantial reduction in the number of oral and genital ulcers, cutaneous lesions, and articular signs and symptoms by the end of the study. Pain scores, global assessments, and prednisone dose also declined. The IFN-α dose at end of study averaged 1.5 million units. Significant side effects, besides the anticipated flu-like syndrome experienced by all the patients, included single instances of seizure, psychosis, psoriasis, and hyperthyroidism. Conclusion. The results suggest that IFN-α is effective therapy for some manifestations of Behcet's disease.",
keywords = "Behcet's disease, Interferon-α",
author = "O'Duffy, {J. Desmond} and Kenneth Calamia and Stanley Cohen and Goronzy, {Jorg J.} and David Herman and Joseph Jorizzo and Cornelia Weyand and Matteson, {Eric Lawrence}",
year = "1998",
month = "10",
language = "English (US)",
volume = "25",
pages = "1938--1944",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "10",

}

TY - JOUR

T1 - Interferon-α treatment of Behcet's disease

AU - O'Duffy, J. Desmond

AU - Calamia, Kenneth

AU - Cohen, Stanley

AU - Goronzy, Jorg J.

AU - Herman, David

AU - Jorizzo, Joseph

AU - Weyand, Cornelia

AU - Matteson, Eric Lawrence

PY - 1998/10

Y1 - 1998/10

N2 - Objective. To determine if interferon-α (IFN-α) is effective in Behcet's disease (BD). Methods. Ten patients having active BD were entered into a 6 month open label trial of IFN-α therapy given by self-administered dose of 3 million units subcutaneously daily. Provision was made for downward or upward dosing depending on predetermined responses. Four study centers followed the same protocol. Patients having ocular or neurologic inflammation at onset of the study were excluded. Results. Seven patients completed the trial, while 3 were removed at 3 and 4 months for side effects or lack of efficacy. There was a substantial reduction in the number of oral and genital ulcers, cutaneous lesions, and articular signs and symptoms by the end of the study. Pain scores, global assessments, and prednisone dose also declined. The IFN-α dose at end of study averaged 1.5 million units. Significant side effects, besides the anticipated flu-like syndrome experienced by all the patients, included single instances of seizure, psychosis, psoriasis, and hyperthyroidism. Conclusion. The results suggest that IFN-α is effective therapy for some manifestations of Behcet's disease.

AB - Objective. To determine if interferon-α (IFN-α) is effective in Behcet's disease (BD). Methods. Ten patients having active BD were entered into a 6 month open label trial of IFN-α therapy given by self-administered dose of 3 million units subcutaneously daily. Provision was made for downward or upward dosing depending on predetermined responses. Four study centers followed the same protocol. Patients having ocular or neurologic inflammation at onset of the study were excluded. Results. Seven patients completed the trial, while 3 were removed at 3 and 4 months for side effects or lack of efficacy. There was a substantial reduction in the number of oral and genital ulcers, cutaneous lesions, and articular signs and symptoms by the end of the study. Pain scores, global assessments, and prednisone dose also declined. The IFN-α dose at end of study averaged 1.5 million units. Significant side effects, besides the anticipated flu-like syndrome experienced by all the patients, included single instances of seizure, psychosis, psoriasis, and hyperthyroidism. Conclusion. The results suggest that IFN-α is effective therapy for some manifestations of Behcet's disease.

KW - Behcet's disease

KW - Interferon-α

UR - http://www.scopus.com/inward/record.url?scp=0031752108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031752108&partnerID=8YFLogxK

M3 - Article

C2 - 9779847

AN - SCOPUS:0031752108

VL - 25

SP - 1938

EP - 1944

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 10

ER -